查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1601256

罕見疾病基因檢測市場：按疾病類型、技術、專業和最終用戶分類 - 全球預測 2025-2030

Rare Disease Genetic Testing Market by Disease Type (Cancer, Cardiovascular Disorders, Dermatology Diseases), Technology (Array Technology, FISH, Karyotyping), Specialty, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年罕見疾病基因檢測市場規模為13.3億美元，預計2024年將達15.4億美元，複合年成長率為16.15%，預計到2030年將達38億美元。

罕見疾病基因檢測是一種診斷測試，可識別導致罕見疾病的基因突變，這些疾病通常影響分佈在世界各地的小部分患者群體。該領域的需求源於其在提供早期診斷、個人化醫療和針對性治療選擇方面的重要作用，特別是當傳統治療失敗時。基因檢測主要應用於臨床和研究環境，以支持知情的臨床決策、病患諮詢和藥物開發，最終用途擴展到醫院、診斷中心和研究機構。基因檢測的成長是由基因序列測定技術的進步、意識的提高以及政府對罕見疾病研究的支持政策所推動的。此外，增加對製藥公司的投資以及與診斷公司的合作也提供了巨大的成長機會。對伴同性診斷和精準醫療的需求不斷成長增加了市場潛力，而 IT 支援的遠端醫療解決方案則促進了測試的進行。

主要市場統計
基準年[2023] 13.3億美元
預測年份 [2024] 15.4億美元
預測年份 [2030] 38億美元
複合年成長率（%） 16.15%

然而，該市場面臨高成本、監管挑戰、基因資料隱私的倫理問題以及新興地區知名度低等限制。解決這些挑戰需要策略定價、監管清晰度和更強力的隱私保護。創新熱點包括開發負擔得起的測序技術、用於預測分析的人工智慧整合、用於資料解釋的先進生物資訊學工具以及個人化數位健康平台。利用市場機會的關鍵建議包括促進與分子診斷公司的合作、利用巨量資料分析以及建立以患者為中心的解決方案以增強遺傳諮詢師與患者的互動。這個市場是研究集中且高度專業的，需要對基因組學和監管環境有深入的了解。生物技術、資料分析和醫療保健的融合有望形成一個生態系統，該生態系統將產生新的治療途徑和創新的護理途徑，為罕見疾病管理的突破和可能擾亂市場條件鋪平道路。透過克服監管和成本挑戰，公司可以將自己定位為這個不斷發展的領域的領導者。

市場動態：快速發展的罕見疾病基因檢測市場的關鍵市場洞察

供需的動態交互作用正在改變罕見疾病基因檢測市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 罕見遺傳疾病的流行以及早期快速診斷的必要性
    • 擴大使用翻譯和基因組研究來識別新突變
    • 政府在罕見疾病診斷和治療方面的舉措
  • 市場限制因素
    • 道德問題和罕見疾病資訊的獲取有限
  • 市場機會
    • 基因技術的進步識別新的罕見疾病基因
    • 罕見遺傳疾病診斷的獲利投資
  • 市場挑戰
    • 與新的罕見疾病基因檢測核准程序相關的嚴格規定

波特五力：駕馭罕見疾病基因檢測市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解罕見疾病基因檢測市場的外部影響

外部宏觀環境因素對罕見疾病基因檢測市場的表現動態起著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解罕見疾病基因檢測市場競爭狀況

罕見疾病基因檢測市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 罕見疾病基因檢測市場定位矩陣供應商績效評估

FPNV定位矩陣是評估罕見疾病基因檢測市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。四個象限清楚且準確地分類供應商，幫助使用者辨識最能滿足其策略目標的合作夥伴和解決方案。

本報告提供了涵蓋關鍵重點領域的全面市場分析：

1. 市場滲透率：對當前市場環境的詳細回顧，包括行業主要企業的大量資料。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 罕見遺傳疾病的流行以及早期快速診斷的必要性
      • 擴大使用轉化研究和基因組監測來識別新變異
      • 政府關於罕見疾病診斷和治療的舉措
    • 抑制因素
      • 倫理問題和罕見疾病資訊的獲取有限
    • 機會
      • 基因技術的進步識別新的罕見疾病基因
      • 罕見遺傳疾病診斷的獲利投資
    • 任務
      • 新罕見疾病基因檢測核准流程的嚴格規定
  • 市場區隔分析
    • 疾病類型：開發先進檢測方法，滿足罕見遺傳疾病篩檢需求
    • 最終用戶：學術研究實驗室稀有基因測試的新研究
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境
  • 客戶客製化

第6章 罕見疾病基因檢測市場：依疾病類型

  • 癌症
  • 心血管疾病
  • 皮膚科疾病
  • 內分泌/代謝疾病
  • 血液疾病
  • 免疫疾病
  • 肌肉骨骼疾病
  • 神經系統疾病

第7章 罕見疾病基因檢測市場：依技術分類

  • 陣列技術
  • 魚
  • 核型分析
  • 次世代定序
    • 全EXOME定序
    • 全基因組序列分析
  • 基於PCR的測試
  • 桑格序列

第8章 罕見疾病基因檢測市場：依專業分類

  • 生化基因檢測
  • 染色體基因檢測
  • 分子遺傳學檢測

第9章 罕見疾病基因檢測市場：依最終用戶分類

  • 診斷實驗室
  • 醫院/診所
  • 研究機構和 CRO

第10章 美洲罕見疾病基因檢測市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章 亞太罕見疾病基因檢測市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章 歐洲、中東、非洲罕見疾病基因檢測市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Burjeel Holdings與美國Bridgebio Pharma合作啟動罕見疾病研發計劃“Nader”
    • 美國國立衛生研究院 (NIH) 投入 1.4 億美元研究正常人體細胞和組織的遺傳變異
    • CENTOGENE 宣布推出新的 CentoGenome 全基因組定序解決方案，用於診斷罕見和神經退化性疾病

公司名單

  • Laboratory Corporation Of America Holdings
  • Biora Therapeutics, Inc.
  • 3billion, Inc.
  • Caris Life Sciences
  • Ambry Genetics Corporation
  • OPKO Health, Inc.
  • Color Health, Inc.
  • Quest Diagnostics Incorporated
  • Nonacus Limited
  • Integrated DNA Technologies, Inc. by Danaher Corporation
  • Myriad Genetics, Inc.
  • Blueprint Genetics Oy
  • PerkinElmer Inc.
  • Macrogen, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Variantyx, Inc.
  • Centogene NV
  • Fulgent Genetics, Inc.
  • Genomelink, Inc.
  • Illumina, Inc.
  • GeneDx, LLC
  • Invitae Corporation
  • Sanofi SA
  • Helix OpCo, LLC
  • Arup Laboratories
  • The Cooper Companies, Inc.
  • QIAGEN NV
  • Realm IDX, Inc.
  • Baylor Genetics
  • Thermo Fisher Scientific Inc.
Product Code: MRR-B9334AD6C623

The Rare Disease Genetic Testing Market was valued at USD 1.33 billion in 2023, expected to reach USD 1.54 billion in 2024, and is projected to grow at a CAGR of 16.15%, to USD 3.80 billion by 2030.

Rare disease genetic testing involves diagnostic tests to identify gene mutations causing rare disorders, often affecting small patient populations scattered globally. This field's necessity stems from the critical role it plays in early diagnosis, personalized medicine, and providing targeted treatment options, especially when traditional therapies fail. Primarily applied in clinical and research settings, genetic testing supports informed clinical decisions, patient counseling, and drug development, with end-use scope spanning hospitals, diagnostic centers, and research institutes. The growth of genetic testing is driven by advances in genome sequencing technologies, increased awareness, and supportive government policies for rare disease research. Additionally, the increase in pharmaceutical investments and collaborations with diagnostic companies represents significant growth opportunities. A rise in demand for companion diagnostics and precision medicine amplifies market potential, while IT-enabled telehealth solutions ease testing accessibility.

KEY MARKET STATISTICS
Base Year [2023] USD 1.33 billion
Estimated Year [2024] USD 1.54 billion
Forecast Year [2030] USD 3.80 billion
CAGR (%) 16.15%

However, the market faces limitations like high costs, regulatory challenges, ethical concerns around genetic data privacy, and limited awareness in developing regions. These challenges necessitate strategic pricing, clearer regulatory frameworks, and privacy protection advancements to foster market expansion. Innovation hotspots include the development of affordable sequencing technologies, integration of AI for predictive analytics, advanced bioinformatics tools for data interpretation, and personalized digital health platforms. Key recommendations to capitalize on market opportunities include fostering collaborations with molecular diagnostic firms, leveraging big data analytics, and establishing patient-centric solutions that enhance interaction between genetic counselors and patients. The nature of this market is research-intensive and highly specialized, requiring a keen understanding of genomic science and regulatory landscapes. The convergence of biotechnology, data analytics, and healthcare promises a generative ecosystem for novel therapeutic avenues and innovative care pathways, paving the way for breakthroughs in rare disease management and potentially disrupting the market landscape. By navigating regulatory and cost challenges, businesses can position themselves as leaders in this evolving field.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Rare Disease Genetic Testing Market

The Rare Disease Genetic Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of Rare Genetic Disease and Need for Early & Rapid Diagnosis
    • Rising Use in Translational & Genomic Research for Identification of Novel Mutations
    • Government Initiatives for Diagnosis and Treatment of Rare Diseases
  • Market Restraints
    • Ethical Concerns and Access to Limited Information on Rare Disease
  • Market Opportunities
    • Advancements in Genetic Technology to Identify New Rare Disease Genes
    • Favorable Investments for Diagnosis of Rare Genetic Diseases
  • Market Challenges
    • Stringent Regulations Associated with the Approval Process of New Rare Diseases Genetic Test

Porter's Five Forces: A Strategic Tool for Navigating the Rare Disease Genetic Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Rare Disease Genetic Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Rare Disease Genetic Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Rare Disease Genetic Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Rare Disease Genetic Testing Market

A detailed market share analysis in the Rare Disease Genetic Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Rare Disease Genetic Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Rare Disease Genetic Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Rare Disease Genetic Testing Market, highlighting leading vendors and their innovative profiles. These include Laboratory Corporation Of America Holdings, Biora Therapeutics, Inc., 3billion, Inc., Caris Life Sciences, Ambry Genetics Corporation, OPKO Health, Inc., Color Health, Inc., Quest Diagnostics Incorporated, Nonacus Limited, Integrated DNA Technologies, Inc. by Danaher Corporation, Myriad Genetics, Inc., Blueprint Genetics Oy, PerkinElmer Inc., Macrogen, Inc., F. Hoffmann-La Roche Ltd., Variantyx, Inc., Centogene N.V., Fulgent Genetics, Inc., Genomelink, Inc., Illumina, Inc., GeneDx, LLC, Invitae Corporation, Sanofi S.A., Helix OpCo, LLC, Arup Laboratories, The Cooper Companies, Inc., QIAGEN N.V., Realm IDX, Inc., Baylor Genetics, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Rare Disease Genetic Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Disease Type, market is studied across Cancer, Cardiovascular Disorders, Dermatology Diseases, Endocrine & Metabolism Diseases, Hematology Diseases, Immunological Disorders, Musculoskeletal Disorders, and Neurological Disorders.
  • Based on Technology, market is studied across Array Technology, FISH, Karyotyping, Next Generation Sequencing, PCR - Based Testing, and Sanger Sequencing. The Next Generation Sequencing is further studied across Whole Exome Sequencing and Whole Genome Sequencing.
  • Based on Specialty, market is studied across Biochemical Genetic Tests, Chromosomal Genetic Tests, and Molecular Genetic Tests.
  • Based on End-User, market is studied across Diagnostic Laboratories, Hospitals & Clinics, and Research Laboratories & CROs.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of Rare Genetic Disease and Need for Early & Rapid Diagnosis
      • 5.1.1.2. Rising Use in Translational & Genomic Research for Identification of Novel Mutations
      • 5.1.1.3. Government Initiatives for Diagnosis and Treatment of Rare Diseases
    • 5.1.2. Restraints
      • 5.1.2.1. Ethical Concerns and Access to Limited Information on Rare Disease
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in Genetic Technology to Identify New Rare Disease Genes
      • 5.1.3.2. Favorable Investments for Diagnosis of Rare Genetic Diseases
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent Regulations Associated with the Approval Process of New Rare Diseases Genetic Test
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Disease Type: Development of advanced tests to cater to the screening needs of rare genetic diseases
    • 5.2.2. End-User: Emerging studies on rare genetic testing in research laboratories in academic institutes
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization

6. Rare Disease Genetic Testing Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Cancer
  • 6.3. Cardiovascular Disorders
  • 6.4. Dermatology Diseases
  • 6.5. Endocrine & Metabolism Diseases
  • 6.6. Hematology Diseases
  • 6.7. Immunological Disorders
  • 6.8. Musculoskeletal Disorders
  • 6.9. Neurological Disorders

7. Rare Disease Genetic Testing Market, by Technology

  • 7.1. Introduction
  • 7.2. Array Technology
  • 7.3. FISH
  • 7.4. Karyotyping
  • 7.5. Next Generation Sequencing
    • 7.5.1. Whole Exome Sequencing
    • 7.5.2. Whole Genome Sequencing
  • 7.6. PCR - Based Testing
  • 7.7. Sanger Sequencing

8. Rare Disease Genetic Testing Market, by Specialty

  • 8.1. Introduction
  • 8.2. Biochemical Genetic Tests
  • 8.3. Chromosomal Genetic Tests
  • 8.4. Molecular Genetic Tests

9. Rare Disease Genetic Testing Market, by End-User

  • 9.1. Introduction
  • 9.2. Diagnostic Laboratories
  • 9.3. Hospitals & Clinics
  • 9.4. Research Laboratories & CROs

10. Americas Rare Disease Genetic Testing Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Rare Disease Genetic Testing Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Rare Disease Genetic Testing Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Burjeel Holdings To Launch Rare Disease Research & Development Project 'Nader' In Partnership With US-Based Bridgebio Pharma
    • 13.3.2. NIH Launches USD 140 Million Effort To Investigate Genetic Variation In Normal Human Cells And Tissues
    • 13.3.3. CENTOGENE Launches NEW CentoGenome, A Whole Genome Sequencing Solution for Diagnosis of Rare and Neurodegenerative Diseases

Companies Mentioned

  • 1. Laboratory Corporation Of America Holdings
  • 2. Biora Therapeutics, Inc.
  • 3. 3billion, Inc.
  • 4. Caris Life Sciences
  • 5. Ambry Genetics Corporation
  • 6. OPKO Health, Inc.
  • 7. Color Health, Inc.
  • 8. Quest Diagnostics Incorporated
  • 9. Nonacus Limited
  • 10. Integrated DNA Technologies, Inc. by Danaher Corporation
  • 11. Myriad Genetics, Inc.
  • 12. Blueprint Genetics Oy
  • 13. PerkinElmer Inc.
  • 14. Macrogen, Inc.
  • 15. F. Hoffmann-La Roche Ltd.
  • 16. Variantyx, Inc.
  • 17. Centogene N.V.
  • 18. Fulgent Genetics, Inc.
  • 19. Genomelink, Inc.
  • 20. Illumina, Inc.
  • 21. GeneDx, LLC
  • 22. Invitae Corporation
  • 23. Sanofi S.A.
  • 24. Helix OpCo, LLC
  • 25. Arup Laboratories
  • 26. The Cooper Companies, Inc.
  • 27. QIAGEN N.V.
  • 28. Realm IDX, Inc.
  • 29. Baylor Genetics
  • 30. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. RARE DISEASE GENETIC TESTING MARKET RESEARCH PROCESS
  • FIGURE 2. RARE DISEASE GENETIC TESTING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. RARE DISEASE GENETIC TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. RARE DISEASE GENETIC TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. RARE DISEASE GENETIC TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. RARE DISEASE GENETIC TESTING MARKET DYNAMICS
  • TABLE 7. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DERMATOLOGY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY ENDOCRINE & METABOLISM DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY HEMATOLOGY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY IMMUNOLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY ARRAY TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY FISH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY KARYOTYPING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY PCR - BASED TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY BIOCHEMICAL GENETIC TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY CHROMOSOMAL GENETIC TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY MOLECULAR GENETIC TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY RESEARCH LABORATORIES & CROS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 74. AUSTRALIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 76. AUSTRALIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 79. CHINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 80. CHINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 81. CHINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. INDIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 84. INDIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 85. INDIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 86. INDIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. INDONESIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 89. INDONESIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 90. INDONESIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 91. INDONESIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. JAPAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 94. JAPAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 95. JAPAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 96. JAPAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. MALAYSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 99. MALAYSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 100. MALAYSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 101. MALAYSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. PHILIPPINES RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 104. PHILIPPINES RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 105. PHILIPPINES RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 106. PHILIPPINES RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. SINGAPORE RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 109. SINGAPORE RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 110. SINGAPORE RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 111. SINGAPORE RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. SOUTH KOREA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 114. SOUTH KOREA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 115. SOUTH KOREA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 116. SOUTH KOREA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. TAIWAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 119. TAIWAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 120. TAIWAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 121. TAIWAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. THAILAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 124. THAILAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 125. THAILAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 126. THAILAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. VIETNAM RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 129. VIETNAM RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 130. VIETNAM RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 131. VIETNAM RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. DENMARK RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 140. DENMARK RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 141. DENMARK RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 142. DENMARK RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. EGYPT RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 145. EGYPT RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 146. EGYPT RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 147. EGYPT RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. FINLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 150. FINLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 151. FINLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 152. FINLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. FRANCE RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 155. FRANCE RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 156. FRANCE RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 157. FRANCE RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. GERMANY RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 160. GERMANY RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 161. GERMANY RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 162. GERMANY RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. ISRAEL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 165. ISRAEL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 166. ISRAEL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 167. ISRAEL RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. ITALY RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 170. ITALY RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 171. ITALY RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 172. ITALY RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. NETHERLANDS RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 175. NETHERLANDS RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 176. NETHERLANDS RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 177. NETHERLANDS RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. NIGERIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 180. NIGERIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 181. NIGERIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 182. NIGERIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. NORWAY RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 185. NORWAY RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 186. NORWAY RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 187. NORWAY RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. POLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 190. POLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 191. POLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 192. POLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. QATAR RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 195. QATAR RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 196. QATAR RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 197. QATAR RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. RUSSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 200. RUSSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 201. RUSSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 202. RUSSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. SAUDI ARABIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 205. SAUDI ARABIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 206. SAUDI ARABIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 207. SAUDI ARABIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 210. SOUTH AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 211. SOUTH AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 212. SOUTH AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. SPAIN RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 215. SPAIN RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 216. SPAIN RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 217. SPAIN RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. SWEDEN RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 220. SWEDEN RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 221. SWEDEN RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 222. SWEDEN RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. SWITZERLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 225. SWITZERLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 226. SWITZERLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 227. SWITZERLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. TURKEY RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 230. TURKEY RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 231. TURKEY RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 232. TURKEY RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED ARAB EMIRATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED ARAB EMIRATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED ARAB EMIRATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED ARAB EMIRATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 240. UNITED KINGDOM RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 241. UNITED KINGDOM RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 242. UNITED KINGDOM RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 243. RARE DISEASE GENETIC TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 244. RARE DISEASE GENETIC TESTING MARKET, FPNV POSITIONING MATRIX, 2023